Physician profile
Stephen Badylak
NPI 1588037816
$962,992.29
in general payments reported to CMS, 2019-2025
9 companies · $97K in 2025
The $97K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $17K · 2021: $53K · 2022: $582K · 2023: $97K · 2024: $96K · 2025: $97K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $198K · Honoraria: $64K · Travel and Lodging: $23K · Food and Beverage: $5,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $197,970.24 |
| Honoraria | $63,650.00 |
| Travel and Lodging | $22,643.21 |
| Food and Beverage | $5,693.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Triad Life Sciences INC. | $597,268.66 | 2021-2022 | |
| Convatec INC. | $191,079.99 | 2023-2025 | |
| Davol INC. | $166,943.28 | 2019-2025 | Phasix Mesh, Arista, Arista Ah Flexitip |
| Bard Peripheral Vascular, INC. | $3,495.24 | 2023-2024 | |
| Elutia, INC. | $2,029.98 | 2020-2022 | |
| Becton, Dickinson and Company | $1,355.92 | 2023-2024 | Phasix Mesh |
| C. R. Bard, INC. & Subsidiaries | $734.74 | 2019-2022 | |
| Amgen INC. | $47.59 | 2019 | |
| Kerecis Limited | $36.89 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Badylak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.